Qube Research & Technologies (QRT)
CTNM

Qube Research & Technologies (QRT)’s Contineum Therapeutics CTNM Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.99M Sell
182,413
-50,121
-22% -$657K ﹤0.01% 1914
2026
Q1 		$3.04M Buy
232,534
+189,456
+440% +$2.54M ﹤0.01% 1927
2025
Q4 		$492K Buy
+43,078
New +$491K ﹤0.01% 2813
2025
Q3 		– Sell
-10,924
Closed -$43.4K – 4023
2025
Q2 		$43.4K Buy
+10,924
New +$47.5K ﹤0.01% 3177

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CTNM Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Contineum Therapeutics (CTNM) stake by 22% in Q2 2026, selling an estimated $657K and leaving 182,413 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1914.

Qube Research & Technologies (QRT) first reported a position in CTNM in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.04M in Q1 2026. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Qube Research & Technologies (QRT) held 182,413 shares of Contineum Therapeutics worth $2.99M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 50,121 Contineum Therapeutics shares in Q2 2026, an estimated $657K.
  • Contineum Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1914 holding.
  • Qube Research & Technologies (QRT) first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Qube Research & Technologies (QRT)'s Contineum Therapeutics position peaked at $3.04M in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.